SMYD3 and prostate adenocarcinoma: The protein KMT SET and MYND domain 3 (SMYD3) is also highly expressed in PCa (12–14); however, whether it has a direct molecular role in promoting aggressive phenotypes associated with advanced prostate adenocarcinoma has not been clearly defined.